Collagen Matrix Names Tim Starr Chief Operating Officer

We are pleased to announce the appointment of Tim Starr as Chief Operating Officer at Collagen Matrix, Inc. Tim is a Biochemist with more than 30 years of leadership experience in life sciences manufacturing and supply chain. Most recently he was Vice President of Operations for Boston Scientific Corporation’s Symetis TAVI (Transcatheter Aortic Valve Implantation) manufacturing and supply chain, a role established when he joined Symetis in 2012. At Symetis, he was responsible for the introduction and growth of the Accurate family (Neo, Neo2, Neo TA) of porcine tissue valve and delivery system products from early-stage commercial production to their current significant market position in Europe. At Symetis, he oversaw the demand-led growth of the factories in Brazil and Switzerland, demonstrating a year-on-year production growth with outstanding quality, service and cost performance.

Tim’s prior work experience included Quality and Compliance functional leadership roles in medical device, pharmaceuticals and infant nutritional supply chain activities for Boston Scientific’s CRM division, Abbott Laboratories, and with Wyeth Pharmaceuticals where he held roles in the Nutritionals and Pharmaceutical division supply organizations, including being on the pioneer leadership team for the construction and operation of their Singapore plants.

Tim is responsible for worldwide operations spending time in both the US and Netherlands facilities. He is originally from Ireland, is married to Michelle and is a proud father and grandfather.

About Collagen Matrix, Inc.

Collagen Matrix, Inc. is a developer and manufacturer of collagen-based medical products used for tissue and bone repair and regeneration. Founded in 1997, Collagen Matrix is headquartered in Oakland, New Jersey and develops proprietary products that are sold to OEM customers on either a contract or private label basis across orthopedic, sports medicine, dental, and neurosurgery end markets. The company also offers partnership opportunities including distribution, contract product development, and contract manufacturing services. For more information, please visit

About Linden Capital Partners

Linden Capital Partners is a Chicago-based private equity firm focused exclusively on the healthcare industry. Founded in 2004, Linden is one of the country’s largest dedicated healthcare private equity firms. Linden’s strategy is based upon three elements: (i) healthcare specialization, (ii) integrated private equity and operating expertise, and (iii) its differentiated human capital program. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Since its founding, Linden has invested in over 40 healthcare companies encompassing over 200 total transactions. The firm has raised over $6 billion in limited partner commitments since inception. For more information, please visit


Looking for a career with purpose? Join our team and work with us to develop life-changing products that help patients heal. Visit our careers page to learn more about what sets Regenity apart.

See open postions

Related posts

Read More

GUIDOR Portfolio

Click this link to learn about Guidor, our synthetic bone grafting system.

Read More
Read More

Natsuyo Lee Reflects on 20 Years at Regenity

Natsuyo Lee (Nat) plays a pivotal role in bringing innovation to life at Regenity Biosciences….

Read More
Read More

Dan Fernandez Returns to Regenity

Meet Daniel Fernandez, our Regulatory Specialist, whose journey is a testament to the incredible…

Read More

Let’s connect

Learn how to transform patient recovery through unique platforms and processes.